AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
UC Is Final Planned Indication For IL-23 Inhibitor
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
You may also be interested in...
Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.
First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
AbbVie Pinpoints US Humira Erosion At 37% In 2023
With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.